The DOI matches its Crossref record.
Reversal of multidrug resistance by surfactants
Open accessAbstract
Cremophor EL, a pharmacologically inactive solubilising agent, has been shown to reverse multidrug resistance (MDR). Using flow cytometric evaluation of equilibrium intracellular levels of daunorubicin (DNR), we found that eight other surface active agents will also reverse MDR. All the active detergents contain polyethoxylated moieties but have no similarities in their hydrophobic components. The properties of three polyethoxylated surfactants that showed the lowest toxicities, Cremophor, Tween 80 and Solutol HS15, were examined in more detail. The concentrations of Tween 80 and Solutol required to reverse DNR exclusion were 10-fold lower than for Cremophor. However while concentrations greater than or equal to 1:10(2) of the former two surfactants resulted in breakdown of cells, even 1:10 of Cremophor did not lyse cells. Studies of the effects of Cremophor on the uptake and efflux of DNR in normal and MDR cell types showed that Cremophor increases intracellular DNR primarily by locking the rapid efflux from the cells. This blockage of drug efflux may be mediated by a substantial alteration in the fluidity of cell membranes induced by Cremophor, as shown by decreased fluorescence anisotropy of a membrane probe. Consistent with these data, coinjection of adriamycin plus Cremophor into mice carrying a multidrug resistant P388 transplantable tumour significantly increased the survival time of the mice compared with adriamycin treatment alone.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Gelderblom, H., Verweij, J., Nooter, K., & Sparreboom, A. (2001) · European Journal of Cancer · doi:10.1016/s0959-8049(01)00171-x · Cited by 1,655
Strategies to Address Low Drug Solubility in Discovery and Development
Williams, H. D., Trevaskis, N. L., Charman, S. A., Shanker, R. M., Charman, W. N., Pouton, C. W., & Porter, C. J. H. (2013) · Pharmacological Reviews · doi:10.1124/pr.112.005660 · Cited by 1,570
Nanoparticulate systems for brain delivery of drugs.
Kreuter, J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(00)00122-8 · Cited by 1,107
Nanoparticulate systems for brain delivery of drugs
Kreuter, J. (2012) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2012.09.015 · Cited by 958
Apolipoprotein-mediated transport of nanoparticle-bound drugs across the blood-brain barrier.
Kreuter, J., Shamenkov, D., Petrov, V., Ramge, P., Cychutek, K., Koch-Brandt, C., & Alyautdin, R. (2002) · Journal of drug targeting · doi:10.1080/10611860290031877 · Cited by 801
Molecular Properties of Bacterial Multidrug Transporters
Putman, M., van Veen, H. W., & Konings, W. N. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.4.672-693.2000 · Cited by 795
Pluronic® block copolymers for overcoming drug resistance in cancer
Kabanov, A. V., Batrakova, E. V., & Alakhov, V. Y. (2002) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00047-9 · Cited by 636
ABC Efflux Pump-Based Resistance to Chemotherapy Drugs
Eckford, P. D. W., & Sharom, F. J. (2009) · Chemical Reviews · doi:10.1021/cr9000226 · Cited by 597
Pharmacological Effects of Formulation Vehicles: Implications for Cancer Chemotherapy
ten Tije, A. J., Verweij, J., Loos, W. J., & Sparreboom, A. (2003) · Clinical Pharmacokinetics · doi:10.2165/00003088-200342070-00005 · Cited by 591
Martinez, M. N., & Amidon, G. L. (2002) · The Journal of Clinical Pharmacology · doi:10.1177/00970002042006005 · Cited by 536
Significant Transport of Doxorubicin into the Brain with Polysorbate 80-Coated Nanoparticles
Gulyaev, A. E., Gelperina, S. E., Skidan, I. N., Antropov, A. S., Kivman, G. Y., & Kreuter, J. (1999) · Pharmaceutical Research · doi:10.1023/a:1018983904537 · Cited by 521
Effects of nonionic surfactants on membrane transporters in Caco-2 cell monolayers
Rege, B. D., Kao, J. P. Y., & Polli, J. E. (2002) · European Journal of Pharmaceutical Sciences · doi:10.1016/s0928-0987(02)00055-6 · Cited by 509
The P-glycoprotein multidrug transporter
Sharom, F. J. (2011) · Essays in Biochemistry · doi:10.1042/bse0500161 · Cited by 509
Trock, B. J., Leonessa, F., & Clarke, R. (1997) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/89.13.917 · Cited by 434
Drug interactions in cancer therapy
Scripture, C. D., & Figg, W. D. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1887 · Cited by 366
Kabanov, A. V., Batrakova, E. V., & Miller, D. W. (2003) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(02)00176-x · Cited by 325
Active secretion and enterocytic drug metabolism barriers to drug absorption
Wacher, V. J., Salphati, L., & Benet, L. Z. (1996) · Advanced Drug Delivery Reviews · doi:10.1016/0169-409x(95)00127-s · Cited by 308
Alakhov, V. Y., Moskaleva, E. Y., Batrakova, E. V., & Kabanov, A. V. (1996) · Bioconjugate Chemistry · doi:10.1021/bc950093n · Cited by 304
Paclitaxel nanoparticles for the potential treatment of brain tumors
Koziara, J. M., Lockman, P. R., Allen, D. D., & Mumper, R. J. (2004) · Journal of Controlled Release · doi:10.1016/j.jconrel.2004.07.006 · Cited by 299
O'Driscoll, C. M., & Griffin, B. T. (2008) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2007.10.012 · Cited by 296
Role of Formulation Vehicles in Taxane Pharmacology
van Zuylen, L., Verweij, J., & Sparreboom, A. (2001) · Investigational New Drugs · doi:10.1023/a:1010618632738 · Cited by 293
Batrakova, E., Lee, S., Li, S., Venne, A., Alakhov, V., & Kabanov, A. (1999) · Pharmaceutical Research · doi:10.1023/a:1018942823676 · Cited by 289
Nerurkar, M. M., Burton, P. S., & Borchardt, R. T. (1996) · Pharmaceutical Research · doi:10.1023/a:1016033702220 · Cited by 287
Marchetti, S., Mazzanti, R., Beijnen, J. H., & Schellens, J. H. M. (2007) · The Oncologist · doi:10.1634/theoncologist.12-8-927 · Cited by 284
Collnot, E.-M., Baldes, C., Wempe, M. F., Kappl, R., Hüttermann, J., Hyatt, J. A., Edgar, K. J., Schaefer, U. F., & Lehr, C.-M. (2007) · Molecular Pharmaceutics · doi:10.1021/mp060121r · Cited by 280
Sharom, F. J. (2014) · Frontiers in Oncology · doi:10.3389/fonc.2014.00041 · Cited by 278
Nanomedicine in the diagnosis and therapy of neurodegenerative disorders
Kabanov, A. V., & Gendelman, H. E. (2007) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2007.05.014 · Cited by 277
Exploiting nanotechnology to overcome tumor drug resistance: Challenges and opportunities
Kirtane, A. R., Kalscheuer, S. M., & Panyam, J. (2013) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2013.09.001 · Cited by 258
Mechanism of polymeric nanoparticle-based drug transport across the blood-brain barrier (bbb).
Kreuter, J. (2013) · Journal of Microencapsulation · doi:10.3109/02652048.2012.692491 · Cited by 172
Metadata
- Authors
- Woodcock, D., Linsenmeyer, M., Chojnowski, G., Kriegler, A., Nink, V, Webster, L., & Sawyer, W.
- Venue
- British Journal of Cancer
- Published
- 1992-07
- Volume
- 66
- Issue
- 1
- Pages
- 62-68
- ISSN
- 0007-0920 (ISSN-L)
- 1532-1827
- OpenAlex
- W2044050922
- Cited by
- 233
- References
- 0
- FWCI
- 2.65
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.